137 related articles for article (PubMed ID: 37580909)
1. Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein.
Mukherjee N; Bhunia D; Garai PK; Mondal P; Barman S; Ghosh S
J Pept Sci; 2024 Jan; 30(1):e3535. PubMed ID: 37580909
[TBL] [Abstract][Full Text] [Related]
2. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells.
Putri HE; Nutho B; Rungrotmongkol T; Sritularak B; Vinayanuwattikun C; Chanvorachote P
Phytomedicine; 2021 May; 85():153534. PubMed ID: 33773191
[TBL] [Abstract][Full Text] [Related]
3. CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery.
Dey DK; Sharma C; Vadlamudi Y; Kang SC
Life Sci; 2023 Apr; 318():121476. PubMed ID: 36758667
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
6. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation.
Wu H; Leng RP
Cell Cycle; 2011 Jun; 10(12):1912-5. PubMed ID: 21558803
[TBL] [Abstract][Full Text] [Related]
7. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
Meek DW; Hupp TR
Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
[TBL] [Abstract][Full Text] [Related]
8. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
[TBL] [Abstract][Full Text] [Related]
9. A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy.
Sun SH; Zheng M; Ding K; Wang S; Sun Y
Cancer Biol Ther; 2008 Jun; 7(6):845-52. PubMed ID: 18340116
[TBL] [Abstract][Full Text] [Related]
10. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
[TBL] [Abstract][Full Text] [Related]
11. Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.
Davis JR; Mossalam M; Lim CS
Mol Pharm; 2013 Apr; 10(4):1340-9. PubMed ID: 23398638
[TBL] [Abstract][Full Text] [Related]
12. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.
Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS
Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
14. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
[TBL] [Abstract][Full Text] [Related]
15. p21
Lee J; Kim J; Kim EM; Kim U; Kang AR; Park JK; Um HD
Biochem Biophys Res Commun; 2021 Mar; 543():23-28. PubMed ID: 33503543
[TBL] [Abstract][Full Text] [Related]
16. mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
Shiheido H; Takashima H; Doi N; Yanagawa H
PLoS One; 2011 Mar; 6(3):e17898. PubMed ID: 21423613
[TBL] [Abstract][Full Text] [Related]
17. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
18. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
19. MDM2-mediated Inhibitory Effect of Arsenic Trioxide on Small Cell Lung Cancer Cell Line by Degrading Mutant p53.
Wang YS; Yin JZ; Shi XQ; Zhao XW; Li B; Yang MH
Anticancer Agents Med Chem; 2023; 23(16):1829-1837. PubMed ID: 37259217
[TBL] [Abstract][Full Text] [Related]
20. Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis.
Fedorova O; Daks A; Petrova V; Petukhov A; Lezina L; Shuvalov O; Davidovich P; Kriger D; Lomert E; Tentler D; Kartsev V; Uyanik B; Tribulovich V; Demidov O; Melino G; Barlev NA
Cell Cycle; 2018; 17(15):1917-1930. PubMed ID: 30109812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
